Dorrapharma is a comprehensive pharmaceutical group integrating R&D, manufacture and sales of pharmaceutical APIs and intermediates, cosmetic ingredients, veterinary drug ingredients, formulations and etc. We own the core technology advantage in the area of bromination, enzyme/metalcatalyzed, nitration and hydrogenation, and obtain multiple core patents for invention. We stick to raising the value both for the company and customers,and devote ourselves completely to the technology innovation and brand build and make everyeffort to foster the core competence of the company with the vision of a leading pharmaceutical integrated operator with its core competitive advantage in global market.

Dorra always adheres to R&D-driven strategy supported by a tri-wing business development encompassing manufacture, marketing and quality assurance, dedicated to the development and production green and highly efficient industrial compounds. We have established dual R&D centers in Nanjing and Taizhou conducting comprehensive work from laboratory research to pilot scale development. The manufacturing sites in Hubei province are approved by China GMP, IS09001,EU authorities, FDA, Japan PMDA, etc. The products and services have been mainly supplied to over 50 countries and regions, serving more than 200 global customers by enjoying a high prestige and good reputation.

We are consecutive to concern about the public and repay the society with strong responsibility and social mission along with the healthy and steady development of our company. With the mission of "creating more valuable products for life and health", we are committed to fulfill our social responsibility as an excellent enterprise.